Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domains.

ABSTRACT: The four-dengue virus (DENV) serotypes cause several hundred million infections annually. Several live-attenuated tetravalent dengue vaccines (LAVs) are at different stages of clinical testing and regulatory approval. A major hurdle faced by the two leading LAVs is uneven replication of vaccine serotypes stimulating a dominant response to one serotype at the expense of the other three, leading to the potential for vaccine antibody (Ab) enhanced more severe infections by wild type DENV serotypes that fail to replicate in the vaccine. Protein subunit vaccines are a promising alternative since antigen dosing can be precisely controlled. However, DENV envelope (E) protein subunit vaccines have not performed well to date, possibly due to differences between the monomeric structure of soluble E

SUBMITTER: Thiono DJ 

PROVIDER: S-EPMC11844416 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature